Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 247


Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization.

Gioeli D, Black BE, Gordon V, Spencer A, Kesler CT, Eblen ST, Paschal BM, Weber MJ.

Mol Endocrinol. 2006 Mar;20(3):503-15. Epub 2005 Nov 10.


Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.

Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.

Cancer Res. 2004 Oct 1;64(19):7156-68.


Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).

Koochekpour S, Lee TJ, Wang R, Culig Z, Delorme N, Caffey S, Marrero L, Aguirre J.

Prostate. 2007 Feb 1;67(2):178-89.


Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.

Ghosh PM, Malik SN, Bedolla RG, Wang Y, Mikhailova M, Prihoda TJ, Troyer DA, Kreisberg JI.

Endocr Relat Cancer. 2005 Mar;12(1):119-34.


Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.

Pandini G, Mineo R, Frasca F, Roberts CT Jr, Marcelli M, Vigneri R, Belfiore A.

Cancer Res. 2005 Mar 1;65(5):1849-57.


Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer.

Narayanan R, Yepuru M, Szafran AT, Szwarc M, Bohl CE, Young NL, Miller DD, Mancini MA, Dalton JT.

Cancer Res. 2010 Jan 15;70(2):842-51. doi: 10.1158/0008-5472.CAN-09-3206. Epub 2010 Jan 12.


Ser/Thr protein phosphatase 5 inactivates hypoxia-induced activation of an apoptosis signal-regulating kinase 1/MKK-4/JNK signaling cascade.

Zhou G, Golden T, Aragon IV, Honkanen RE.

J Biol Chem. 2004 Nov 5;279(45):46595-605. Epub 2004 Aug 24.


Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer.

Ha S, Iqbal NJ, Mita P, Ruoff R, Gerald WL, Lepor H, Taneja SS, Lee P, Melamed J, Garabedian MJ, Logan SK.

Oncogene. 2013 Aug 22;32(34):3992-4000. doi: 10.1038/onc.2012.412. Epub 2012 Sep 17.


Stress-activated kinase pathway alteration is a frequent event in bladder cancer.

Otto KB, Acharya SS, Robinson VL.

Urol Oncol. 2012 Jul-Aug;30(4):415-20. doi: 10.1016/j.urolonc.2010.03.002. Epub 2011 Dec 11.


Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes.

Dai Y, Ngo D, Jacob J, Forman LW, Faller DV.

Carcinogenesis. 2008 Sep;29(9):1725-33. doi: 10.1093/carcin/bgn117. Epub 2008 May 16.


Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.

Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H.

Cancer Res. 1994 Oct 15;54(20):5474-8.


Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.

Wang LG, Liu XM, Kreis W, Budman DR.

Biochem Biophys Res Commun. 1999 May 27;259(1):21-8.


A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes.

Cherian MT, Wilson EM, Shapiro DJ.

J Biol Chem. 2012 Jul 6;287(28):23368-80. doi: 10.1074/jbc.M112.344671. Epub 2012 May 15.


Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways.

Ueda T, Bruchovsky N, Sadar MD.

J Biol Chem. 2002 Mar 1;277(9):7076-85. Epub 2001 Dec 19.


Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.

Godoy-Tundidor S, Hobisch A, Pfeil K, Bartsch G, Culig Z.

Clin Cancer Res. 2002 Jul;8(7):2356-61.

Supplemental Content

Support Center